Craif

craif.com

Craif Inc. aims to create a society where people do not lose their lives to cancer through early, painless, and accurate diagnosis using urine tests. Their key product, MySignal®, is a high-precision cancer risk test developed in collaboration with approximately 30 university hospitals and cancer research centers in Japan. By pioneering exosome collection technology, Craif differentiates itself in the market by providing a non-invasive method for early disease detection, thereby optimizing treatment for various conditions. The company is positioned to significantly impact cancer detection and prevention, contributing to a healthier society.